Regeneron reports third quarter 2021 financial and operating results

Tarrytown, n.y., nov. 4, 2021 /prnewswire/ -- third quarter 2021 revenues increased 51% to $3.45 billion versus third quarter 2020 including $804 million attributable to regen-cov ® (2) third quarter 2021 eylea® u.s. net sales increased 12% versus third quarter 2020 to $1.47 billion third quarter 2021 dupixent® global net sales (3) , which are recorded by sanofi, increased 55% to $1.66 billion versus third quarter 2020 third quarter 2021 gaap diluted eps was $14.33 and non-gaap diluted eps (1) was $15.37 positive results reported from four phase 3 dupixent studies; fda expanded approval of dupixent to include children aged 6 to 11 years with asthma regeneron pharmaceuticals, inc. (nasdaq: regn) today announced financial results for the third quarter of 2021 and provided a business update.
REGN Ratings Summary
REGN Quant Ranking